Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant Klebsiella pneumoniae Treated with Ceftazidime-Avibactam: A Retrospective Study

References

• Mohd Asri NA, Ahmad S, Mohamud R, et al. Global prevalence of nosocomial multidrug-resistant Klebsiella pneumoniae: a systematic review and meta-analysis. Antibiotics. 2021;10(12):1508. doi:10.3390/antibiotics10121508
   Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. doi:10.1093/infdis/jiw282
   PubMed Web of Science ®Google Scholar
• Sisto A, D’Ancona F, Meledandri M, et al. Carbapenem non-susceptible Klebsiella pneumoniae from micronet network hospitals, Italy, 2009 to 2012. Euro Surveill. 2012;17(33):20247. doi:10.2807/ese.17.33.20247-en
   PubMedGoogle Scholar
• Wang Q, Xu P, Zhou Y. Analysis of the clinical application of ceftazidime-avibactam in China. J Infect Public Health. 2022;15(4):455–459. doi:10.1016/j.jiph.2022.02.003
   PubMed Web of Science ®Google Scholar
• Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713–2722. doi:10.1093/jac/dkw239
   PubMed Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x
   PubMed Web of Science ®Google Scholar
• Shi Y, Hu J, Liu P, et al. Ceftazidime-avibactam-based versus tigecycline-based regimen for the treatment of carbapenem-resistant Klebsiella pneumoniae-induced pneumonia in critically ill patients. Infect Dis Ther. 2021;10(4):2721–2734. doi:10.1007/s40121-021-00542-3
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17. doi:10.1128/AAC.00883-17
   PubMed Web of Science ®Google Scholar
• Fang J, Li H, Zhang M, et al. Efficacy of ceftazidime-avibactam versus polymyxin B and risk factors affecting clinical outcomes in patients with carbapenem-resistant Klebsiella pneumoniae infections a retrospective study. Front Pharmacol. 2021;12:780940. doi:10.3389/fphar.2021.780940
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lewis RE, Volpe SL, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against kpc-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1–3. doi:10.1016/j.ijid.2017.09.017
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542–544. doi:10.1093/jac/dkx393
   PubMed Web of Science ®Google Scholar
• Wang F, Zhou Q, Yang X, Bai Y, Cui J. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing k. Pneumoniae by in vitro time-kill experiment. PLoS One. 2021;16(10):56.
   Web of Science ®Google Scholar
• Meng H, Zhao Y, An Q, Zhu B, Cao Z, Lu J. Use of ceftazidime-avibactam for suspected or confirmed carbapenem-resistant organisms in children: a retrospective study. Infect Drug Resist. 2023;16:5815–5824. doi:10.2147/IDR.S426326
   PubMed Web of Science ®Google Scholar
• Meng H, Yang J, Niu M, Zhu H, Zhou Y, Lu J. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteraemia in children: a retrospective study. Int J Antimicrob Agents. 2023;62(4):106933. doi:10.1016/j.ijantimicag.2023.106933
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang A, Han L, et al. Clinical outcomes and risk factors for death following carbapenem-resistant Klebsiella pneumoniae infection in solid organ transplant recipients. Microbiol Spectr. 2023;11(1):e0475522. doi:10.1128/spectrum.04755-22
   PubMed Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing Enterobacterales. Clin Infect Dis. 2021;72(11):1871–1878. doi:10.1093/cid/ciaa586
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Alsahli H, Albabtain L, Alassaf S, Al Duhailib Z, Althawadi S. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109:1–7. doi:10.1016/j.ijid.2021.05.079
   PubMed Web of Science ®Google Scholar
• Caston JJ, Cano A, Perez-Camacho I, et al. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (cavicor study). J Antimicrob Chemother. 2022;77(5):1452–1460. doi:10.1093/jac/dkac049
   PubMed Web of Science ®Google Scholar
• Sree RA, Gupta A, Gupta N, et al. Ceftazidime-avibactam alone or in combination with aztreonam versus polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial infections (CAPRI study): a retrospective cohort study from south India. Infection. 2023. doi:10.1007/s15010-023-02094-9
   PubMed Web of Science ®Google Scholar
• Li J, Ren J, Wang W, et al. Risk factors and clinical outcomes of hypervirulent Klebsiella pneumoniae induced bloodstream infections. Eur J Clin Microbiol Infect Dis. 2018;37(4):679–689. doi:10.1007/s10096-017-3160-z
   PubMed Web of Science ®Google Scholar
• Brescini L, Morroni G, Valeriani C, et al. Clinical and epidemiological characteristics of kpc-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy. BMC Infect Dis. 2019;19(1):611. doi:10.1186/s12879-019-4268-9
   PubMed Web of Science ®Google Scholar
• Papadimitriou-Olivgeris M, Fligou F, Bartzavali C, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality. Eur J Clin Microbiol Infect Dis. 2017;36(7):1125–1131. doi:10.1007/s10096-017-2899-6
   PubMed Web of Science ®Google Scholar
• Su CF, Chuang C, Lin YT, et al. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan. Eur J Clin Microbiol Infect Dis. 2018;37(4):651–659. doi:10.1007/s10096-017-3156-8
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by kpc-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143. doi:10.1093/jac/dkv086
   PubMed Web of Science ®Google Scholar
• Luan YY, Chen YH, Li X, et al. Clinical characteristics and risk factors for critically ill patients with carbapenem-resistant Klebsiella pneumoniae (CRKP): a cohort study from developing country. Infect Drug Resist. 2021;14:5555–5562. doi:10.2147/IDR.S343489
   PubMed Web of Science ®Google Scholar
• Zheng G, Zhang J, Wang B, et al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021;10(3):1699–1713. doi:10.1007/s40121-021-00479-7
   PubMed Web of Science ®Google Scholar
• Qian Y, Bi Y, Liu S, Li X, Dong S, Ju M. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review. Ann Palliat Med. 2021;10(7):7340–7350. doi:10.21037/apm-21-338
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Yao X, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis. 2016;35(10):1679–1689. doi:10.1007/s10096-016-2710-0
   PubMed Web of Science ®Google Scholar
• Meng H, Han L, Niu M, et al. Risk factors for mortality and outcomes in hematological malignancy patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Infect Drug Resist. 2022;15:4241–4251. doi:10.2147/IDR.S374904
   PubMed Web of Science ®Google Scholar
• Lin Q, Wang Y, Luo Y, et al. The effect of host immunity on predicting the mortality of carbapenem-resistant organism infection. Front Cell Infect Microbiol. 2020;10:480. doi:10.3389/fcimb.2020.00480
   PubMed Web of Science ®Google Scholar
• Cheng W, Wang H, Zhang J, et al. Lymphocyte subset counts as diagnostic and prognostic markers for carbapenem-resistant Enterobacteriaceae (CRE) infection in critically ill patients. Int J Infect Dis. 2020;96:315–322. doi:10.1016/j.ijid.2020.04.072
   PubMed Web of Science ®Google Scholar
• Kuai J, Zhang Y, Lu B, et al. In vitro synergistic activity of ceftazidime-avibactam in combination with aztreonam or meropenem against clinical Enterobacterales producing bla(KPC) or bla(NDM). Infect Drug Resist. 2023;16:3171–3182. doi:10.2147/IDR.S408228
   PubMed Web of Science ®Google Scholar
• Li J, Lovern M, Riccobene T, et al. Considerations in the selection of renal dosage adjustments for patients with serious infections and lessons learned from the development of ceftazidime-avibactam. Antimicrob Agents Chemother. 2020;64(4). doi:10.1128/AAC.02105-19
   Web of Science ®Google Scholar
• Gatti M, Fornaro G, Viale P, Pea F, Giannella M. Clinical efficacy of renal dosing adjustments of ceftazidime-avibactam in patients affected by carbapenem-resistant Gram-negative infections: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 2023;89(2):617–629. doi:10.1111/bcp.15586
   PubMed Web of Science ®Google Scholar